Five highly anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA. Image courtesy: ACC
February 29, 2024 — The American College of Cardiology (ACC) will soon be holding its ACC 73rd Annual Scientific Session & Expo, ACC.24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center. This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly anticipated clinical trials. According to ACC, five Late-Breaking Clinical Trial sessions, two LBCT Deep Dive sessions, three Featured Clinical Research sessions, and the Clinical and an Investigative Horizons session will be presented throughout the Scientific Sessions this year.
In addition, the ACC notes that 2024 marks the 40th Anniversary of American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines. According to the program schedule, ACC members in attendance will be able to learn how to implement, optimize, and translate guidelines into your clinical practice from key members of the guideline committees and experienced colleagues. The Guidelines Sessions at ACC.24 will focus on the following three current guideline updates:
American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines
2023 Atrial Fibrillation Guideline
- Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? (Session 104)
- Newer Strategies in AF Management: From Prediction to Prevention and Treatment (Session 624)
2022 Aortic Disease Guideline
The Aorta Strikes Back: Adventures in Aortopathies (Session 686)
2020 Valvular Heart Disease Guideline
- Dilemmas in the Lifetime Management of Aortic Stenosis (Session 682)
- 2024: A Valve Odyssey (Session 678)
- Heart and Soul: Utilizing Guidelines and Clinical Pathways in the Care of Valve Patients (Session 756)
Late-breaking Science Sessions
What follows is the listing of late-breaking science sessions to be presented during ACC.24:
Saturday, April 6
9:30 – 10:30 a.m. ET
Main Tent (Hall B1)
- Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial
Featured Clinical Research I (Session 403)
Saturday, April 6
4:15 – 5:30 p.m. ET
Murphy Ballroom 4
- Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial
- Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes
- Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, Obesity and Type 2 Diabetes: Main Results From the Step-HFpEF Dm Trial
- Mandibular Advancement Device Versus CPAP For Blood Pressure Reduction in Obstructive Sleep Apnea and High Cardiovascular Risk─ A Randomized Clinical Non-inferiority Trial
- Remote Acute Assessment of Patients with High Cardiovascular Risk Post-acute Coronary Syndrome (TELE-ACS)
Late-Breaking Clinical Trials II (Session 405)
Sunday, April 7
8 – 9:15 a.m. ET
Main Tent (Hall B1)
- Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial
- Zilebesiran in Combination with a Standard-of-care Antihypertensive in Patients With Inadequately Controlled Hypertension: Primary Results From the Phase 2 Kardia-2 Study
- Efficacy and Safety of Olezarsen in Patients with Hypertriglyceridemia and High Cardiovascular Risk: Primary Results of the BRIDGE-TIMI 73a Trial
- Randomized, Double-blind, Placebo-controlled, Phase 3, Study to Evaluate Lerodalcibep Long-term Efficacy and Safety in Patients With, or at Very-high or High Risk, For Cardiovascular Disease on Stable Lipid-lowering Therapy
- Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound and Durable Reductions in APOC-3 and Triglycerides (TG) in Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results
Sunday, April 7
9:45 – 11 a.m. ET
Main Tent (Hall B1)
- Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients with Small Aortic Annuli: Primary Outcomes from the Randomized Smart Trial
- Effect of Edetate Disodium Based Chelation Infusions on Cardiovascular Events in Post-MI Patients with Diabetes: The TACT2 Trial
- Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction: The REDUCE-AMI Trial
- Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock: Results of the Danger-shock Trial
- One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes: Principal Results From the Double-blind, Placebo-controlled Ultimate DAPT Trial
Featured Clinical Research II (Session 407)
Sunday, April 7
12:15 – 1:30 p.m. ET
Main Tent (Hall B1)
- Benzodiazepine-free Cardiac Anesthesia for Reduction of Postoperative Delirium (B-Free): A Multi-centre Randomized Cluster Crossover Trial
- The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Study: A Randomized Evaluation of a Team-based Remote Education and Medication Management Program to Reduce CV and Kidney Risk
- Improving Cardiac Rehabilitation Participation in Lower-socioeconomic Status Patients: Case Management Vs. Financial Incentives
- Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic (PRO-HF) Trial
- Restrictive Versus Liberal Blood Transfusion Strategy in Type 1 Versus Type 2 Myocardial Infarction: A Prespecified Subgroup Analysis from the Myocardial Ischemia and Transfusion (MINT) Trial
Late-Breaking Clinical Trials Deep Dive I (Session 408)
Sunday, April 7
2 – 3:15 p.m. ET
Main Tent (Hall B1)
This session offers more insights from key clinical trials presented at ACC.24 and find out what it all means for your patients.
Clinical and Investigative Horizons (Session 410)
Sunday, April 7
4:30 – 5:45 p.m. ET
Murphy Ballroom 4
- Health 360x Registry: Scalable Workforce for Equitable Access to Point of Care Decentralized Clinical Trials
- Prevalence of Cardiovascular Disease and Risk Factors Among National Football League Alumni and Their Family Members: Results from the Huddle Study
- Hózhó (Heart Failure Optimization at Home to Improve Outcomes): A Pragmatic Clinical Trial of Telephone-based Guideline-directed Medical Therapy Optimization in Navajo Nation
- Advancing Acute MI Care in Densely Populated LMICs: Innovative Standalone Chest Pain Units For Expedited Triage and Timely Management – A Role Model For Global Healthcare Systems
- A Clinical Trial to Evaluate the Influence of a Spirituality Intervention on Blood Pressure Control, Central Hemodynamics and Endothelial Function: The Feel Trial
Monday, April 8
8:30 – 9:45 a.m. ET
Main Tent (Hall B1)
- A Selective Aldose Reductase Inhibitor (at-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
- Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results of IMPROVE-HCM
- Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery
- Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced Cardiotoxicity (PROACT)
- Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial
Late-Breaking Clinical Trials V (Session 412)
Monday, April 8
11 a.m. – 12:15 p.m. ET
Main Tent (Hall B1)
- Coronary Sinus Reducer for the Treatment of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC)
- Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk: One Year Outcomes of the Randomized DEDICATE-DZHK6 Trial
- Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results from the Target Bp I Randomized Trial
- Preventive PCI or Medical Therapy Alone for Atherosclerotic Coronary Vulnerable Plaques
- Comparison of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty for the Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease
Featured Clinical Research III (Session 413)
Monday, April 8
12:45 – 2 p.m. ET
Room B406A
- Fractional Flow Reserve-guided Complete or Culprit-only PCI in Patients With ST-elevation Myocardial Infarction
- A Multicenter Prospective Randomized Study Comparing the Incidence of Periprocedural Cerebral Embolisms Caused by Catheter Ablation of Atrial Fibrillation Between Cryoballoon and Radiofrequency Ablation
- Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli (the TRAVERSE Trial)
- Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, IVUS-ACS Trial
- Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial
Late-Breaking Clinical Trials Deep Dive II (Session 414)
Monday, April 8
2:30 – 3:45 p.m. ET
Murphy Ballroom 4
ACC.24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 and how those may impact clinical practice and patient care in this deep dive clinical trial session.
More information: www.acc.org
April 25, 2024 
